相关实验视频
Updated: Jul 25, 2026

12:03
Myocardial Infarction and Functional Outcome Assessment in Pigs
Published on: April 25, 2014
概括
索塔洛没有显著降低心肌梗塞后的死亡率,但在这个随机试验中显著降低了已确认的复发性心脏病发作. 对于这种β-阻断剂在后心脏病患者中需要进一步的研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性心肌梗塞 (MI) 幸存者需要有效的治疗来预防死亡和再发作.
- β阻塞剂是心脏病后治疗的基石,但最佳药物选择仍然是研究领域.
研究的目的:
- 为了比较索塔醇 (320毫克每天服用一次) 与安慰剂在减少急性心肌梗塞幸存患者的死亡率和再发作的疗效.
主要方法:
- 进行了一项双盲,随机,安慰剂控制的研究.
- 1456名患者在MI后5-14天随机分配,其中60%接受索塔醇和40%接受安慰剂.
- 对患者进行了12个月的随访,分析基于治疗意图原则.
主要成果:
- 死亡率发生在索塔醇组的7.3%,而安慰剂组的8.9% (18%较低,不具有统计学意义).
- 在索塔醇组中观察到确认的复发性心脏病发作的统计显著减少.
- 在各组之间所有可疑的复发性心脏病发作中没有发现显著差异.
结论:
- 与安慰剂相比,每天服用一次 (320毫克) 的索塔醇并没有显著降低后心脏病发作患者的整体死亡率.
- 索塔醇在降低MI后确诊的复发病例方面显示出显著的益处.
- 进一步的研究可能是有必要的,以澄清sotalol在心肌梗塞后的二次预防中的作用.
相关概念视频
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

